Back to search

Peptide record

TPDB04185

Antibacterial Anticancer Antifungal Antiparasitic Antiviral Hemolysis Toxicity standard
14 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB04185
Antibacterial Anticancer Antifungal Antiparasitic Antiviral Hemolysis Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 dbAMP DRAMP Peptipedia CancerPPD 2.0 AFP-GFuse Antifungipept CAFPdb APD_complete APD_hemolytic Hemolytic2 PD_Hemolysis ToxinPred 3.0
standard
No
A 14-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.
Sequence
SILPTIVSFLSKVF
Physicochemical Analysis
C76H123N15O19
ARNDCEQGHMWY
S
1550.90
10.10
1
0
8
+1
-1.89
1.571
152.86
Mammalian: 1.9 hour Yeast: >20 hour E.coli: >10 hour
0
0.00
4
Residue Composition
number
0
A
0
R
0
N
0
D
0
C
0
E
0
Q
0
G
0
H
2
I
2
L
1
K
0
M
2
F
1
P
3
S
1
T
0
W
0
Y
2
V
Amino Acid Distribution
A: 0 R: 0 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 0 I: 2 L: 2 K: 1 M: 0 F: 2 P: 1 S: 3 T: 1 W: 0 Y: 0 V: 2
Chemical Descriptors
14
C76H123N15O19
1550.90
10.10
+1
-1.89
1.571
Evidence Records 19 records
Evidence 1 Activity

Activity

MIC
Antibacterial
3.1 µM

Target

Staphylococcus aureus USA300

Source & Reference

dbAMP DRAMP

Other

Source Activity Label Source Definition
Antibacterial
dbAMP classified as Antibacterial under the Anti-bacterial function class. DRAMP antibacterial activity supported by MIC records against bacterial target organisms.
ed amount of material. We filled up this gap by using a synthetic peptide. Active against S. aureus USA300 (MIC 3.1 uM), S. epidermidis 1457 (MIC 3.1 uM), B. subtilis 168 (MIC 6.2 uM), C. albicans (MIC 50 uM)
Evidence 2 Activity

Activity

MIC
Antibacterial
3.1 µM

Target

Staphylococcus epidermidis 1457

Source & Reference

dbAMP DRAMP

Other

d up this gap by using a synthetic peptide. Active against S. aureus USA300 (MIC 3.1 uM), S. epidermidis 1457 (MIC 3.1 uM), B. subtilis 168 (MIC 6.2 uM), C. albicans (MIC 50 uM) and C. tropicalis (6.2-12.5 uM). H
Evidence 3 Activity

Activity

MIC
Antibacterial
6.2 µM

Target

B. subtilis 168

Source & Reference

dbAMP DRAMP

Other

peptide. Active against S. aureus USA300 (MIC 3.1 uM), S. epidermidis 1457 (MIC 3.1 uM), B. subtilis 168 (MIC 6.2 uM), C. albicans (MIC 50 uM) and C. tropicalis (6.2-12.5 uM). HL50 =12.5 uM ( Mishra, Wang et
Evidence 4 Activity

Activity

MIC
Antibacterial
50 µM

Target

Candida albicans

Source & Reference

dbAMP DRAMP

Other

reus USA300 (MIC 3.1 uM), S. epidermidis 1457 (MIC 3.1 uM), B. subtilis 168 (MIC 6.2 uM), C. albicans (MIC 50 uM) and C. tropicalis (6.2-12.5 uM). HL50 =12.5 uM ( Mishra, Wang et al. 2018 ). Updated 5/20
Evidence 5 Activity

Activity

MIC
Antifungal
3.1 µM

Target

Staphylococcus aureus USA300

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

Source Activity Label Source Definition
Antifungal
dbAMP classified under the Anti-fungal function class. DRAMP antifungal activity supported by activity records against fungal target organisms.
ed amount of material. We filled up this gap by using a synthetic peptide. Active against S. aureus USA300 (MIC 3.1 uM), S. epidermidis 1457 (MIC 3.1 uM), B. subtilis 168 (MIC 6.2 uM), C. albicans (MIC 50 uM)
Evidence 6 Activity

Activity

MIC
Antifungal
3.1 µM

Target

Staphylococcus epidermidis 1457

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

d up this gap by using a synthetic peptide. Active against S. aureus USA300 (MIC 3.1 uM), S. epidermidis 1457 (MIC 3.1 uM), B. subtilis 168 (MIC 6.2 uM), C. albicans (MIC 50 uM) and C. tropicalis (6.2-12.5 uM). H
Evidence 7 Activity

Activity

MIC
Antifungal
6.2 µM

Target

B. subtilis 168

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

peptide. Active against S. aureus USA300 (MIC 3.1 uM), S. epidermidis 1457 (MIC 3.1 uM), B. subtilis 168 (MIC 6.2 uM), C. albicans (MIC 50 uM) and C. tropicalis (6.2-12.5 uM). HL50 =12.5 uM ( Mishra, Wang et
Evidence 8 Activity

Activity

MIC
Antifungal
50 µM

Target

Candida albicans

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

reus USA300 (MIC 3.1 uM), S. epidermidis 1457 (MIC 3.1 uM), B. subtilis 168 (MIC 6.2 uM), C. albicans (MIC 50 uM) and C. tropicalis (6.2-12.5 uM). HL50 =12.5 uM ( Mishra, Wang et al. 2018 ). Updated 5/20
Evidence 9 Activity

Activity

MIC
Antiparasitic
3.1 µM

Target

Staphylococcus aureus USA300

Source & Reference

DRAMP

Other

Source Activity Label Source Definition
Antiparasitic
DRAMP antiparasitic activity supported by activity records against parasitic targets.
ed amount of material. We filled up this gap by using a synthetic peptide. Active against S. aureus USA300 (MIC 3.1 uM), S. epidermidis 1457 (MIC 3.1 uM), B. subtilis 168 (MIC 6.2 uM), C. albicans (MIC 50 uM)
Evidence 10 Activity

Activity

MIC
Antiparasitic
3.1 µM

Target

Staphylococcus epidermidis 1457

Source & Reference

DRAMP

Other

d up this gap by using a synthetic peptide. Active against S. aureus USA300 (MIC 3.1 uM), S. epidermidis 1457 (MIC 3.1 uM), B. subtilis 168 (MIC 6.2 uM), C. albicans (MIC 50 uM) and C. tropicalis (6.2-12.5 uM). H
Evidence 11 Activity

Activity

MIC
Antiparasitic
6.2 µM

Target

B. subtilis 168

Source & Reference

DRAMP

Other

peptide. Active against S. aureus USA300 (MIC 3.1 uM), S. epidermidis 1457 (MIC 3.1 uM), B. subtilis 168 (MIC 6.2 uM), C. albicans (MIC 50 uM) and C. tropicalis (6.2-12.5 uM). HL50 =12.5 uM ( Mishra, Wang et
Evidence 12 Activity

Activity

MIC
Antiparasitic
50 µM

Target

Candida albicans

Source & Reference

DRAMP

Other

reus USA300 (MIC 3.1 uM), S. epidermidis 1457 (MIC 3.1 uM), B. subtilis 168 (MIC 6.2 uM), C. albicans (MIC 50 uM) and C. tropicalis (6.2-12.5 uM). HL50 =12.5 uM ( Mishra, Wang et al. 2018 ). Updated 5/20
Evidence 13 Activity

Activity

MIC
Antiviral
3.1 µM

Target

Staphylococcus aureus USA300

Source & Reference

DRAMP

Other

Source Activity Label Source Definition
Antiviral
DRAMP antiviral activity supported by activity records against viral targets.
ed amount of material. We filled up this gap by using a synthetic peptide. Active against S. aureus USA300 (MIC 3.1 uM), S. epidermidis 1457 (MIC 3.1 uM), B. subtilis 168 (MIC 6.2 uM), C. albicans (MIC 50 uM)
Evidence 14 Activity

Activity

MIC
Antiviral
3.1 µM

Target

Staphylococcus epidermidis 1457

Source & Reference

DRAMP

Other

d up this gap by using a synthetic peptide. Active against S. aureus USA300 (MIC 3.1 uM), S. epidermidis 1457 (MIC 3.1 uM), B. subtilis 168 (MIC 6.2 uM), C. albicans (MIC 50 uM) and C. tropicalis (6.2-12.5 uM). H
Evidence 15 Activity

Activity

MIC
Antiviral
6.2 µM

Target

B. subtilis 168

Source & Reference

DRAMP

Other

peptide. Active against S. aureus USA300 (MIC 3.1 uM), S. epidermidis 1457 (MIC 3.1 uM), B. subtilis 168 (MIC 6.2 uM), C. albicans (MIC 50 uM) and C. tropicalis (6.2-12.5 uM). HL50 =12.5 uM ( Mishra, Wang et
Evidence 16 Activity

Activity

MIC
Antiviral
50 µM

Target

Candida albicans

Source & Reference

DRAMP

Other

reus USA300 (MIC 3.1 uM), S. epidermidis 1457 (MIC 3.1 uM), B. subtilis 168 (MIC 6.2 uM), C. albicans (MIC 50 uM) and C. tropicalis (6.2-12.5 uM). HL50 =12.5 uM ( Mishra, Wang et al. 2018 ). Updated 5/20
Evidence 17 Activity

Activity

50% Hemolysis
Toxicity
12.5 µM
Hemolytic Cytotoxic
50% Hemolysis | 12.5 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Antibacterial, antifungal, anticancer activities and structural bioinformatics analysis of six naturally occurring temporins. | Peptides | 2018
Evidence 18 Activity

Activity

LC50
Toxicity
40 µM
Cytotoxic
LC50 | 40 | µM | target cell: Human keratinocytes HaCat

Target

Human keratinocytes HaCat

Source & Reference

NA
DBAASP
Antibacterial, antifungal, anticancer activities and structural bioinformatics analysis of six naturally occurring temporins. | Peptides | 2018
Evidence 19 Hemolysis

Source & Reference

APD_complete APD_hemolytic PD_Hemolysis
APD_complete APD_hemolytic PD_Hemolysis

Other

Source Activity Label Source Definition
Hemolysis
APD_complete APD-derived hemolytic peptide annotation. APD_hemolytic APD hemolytic peptide annotation.